추천 제품
product name
Stop Reagent for TMB Substrate, powder, ELISA, 450 nm
Quality Level
형태
powder
저장 온도
room temp
일반 설명
Stop Reagent for TMB Substrate is used to stop TMB substrate reaction for ELISA and change the absorbance from blue (620 nm) to yellow (450 nm).
애플리케이션
Stop Reagent for TMB Substrate has been used:
- for in vitro preparation and analysis of neutrophil extracellular traps (NETs)
- for direct binding enzyme linked immune sorbent assay (ELISA)
- for interference assay
신호어
Danger
유해 및 위험 성명서
Hazard Classifications
Acute Tox. 4 Dermal - Acute Tox. 4 Oral - Eye Dam. 1 - Skin Corr. 1 - Skin Sens. 1 - STOT SE 3
표적 기관
Respiratory system
Storage Class Code
8A - Combustible corrosive hazardous materials
WGK
WGK 3
Flash Point (°F)
260.6 °F - closed cup
Flash Point (°C)
127 °C - closed cup
시험 성적서(COA)
제품의 로트/배치 번호를 입력하여 시험 성적서(COA)을 검색하십시오. 로트 및 배치 번호는 제품 라벨에 있는 ‘로트’ 또는 ‘배치’라는 용어 뒤에서 찾을 수 있습니다.
이미 열람한 고객
Protein and peptide letters, 27(10), 962-970 (2020-04-29)
Microbe-Binding Peptides (MBPs) are currently being investigated to address the problem of antimicrobial resistance. Strategies enhancing their antimicrobial activity have been developed, including peptide dimerization. Here, we present an alternative approach based on peptide polymerization, yielding hapten-labelled polymeric MBPs that
American journal of physiology. Heart and circulatory physiology, 320(5), H1862-H1872 (2021-03-27)
There are currently no Food and Drug Administration-approved treatments for heart failure with preserved ejection fraction (HFpEF). Here we compared the effects of exercise with and without α/β-adrenergic blockade with carvedilol in Col4a3-/- Alport mice, a model of the phenogroup
Nucleic acids research, 43(19), 9123-9132 (2015-10-09)
The in vivo potency of antisense oligonucleotides (ASO) has been significantly increased by reducing their length to 8-15 nucleotides and by the incorporation of high affinity RNA binders such as 2', 4'-bridged nucleic acids (also known as locked nucleic acid
Myeloid-specific deletion of peptidylarginine deiminase 4 (PAD4) mitigates atherosclerosis.
Frontiers in Immunology, 9, 1680-1680 (2018)
Vaccines, 10(10) (2022-10-28)
We report the successful closure of Phase I clinical trials, comprising Phases Ia and Ib, of the vaccine candidate against human schistosomiasis: the Schistosoma mansoni 14 kDa fatty acid-binding protein (Sm14) + glucopyranosyl lipid A in squalene emulsion (GLA-SE). Shown
자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..
고객지원팀으로 연락바랍니다.